Corcept Therapeutics specializes in cortisol-modulating drugs. Click here to read why CORT stock offers investment potential.

This medication is teratogenic and is not currently approved for use in the treatment of Cushing's syndrome. [51] ACTH: Adrenocorticotrophic hormone; b.i.d.: Twice daily; GI: Gastrointestinal ...

Salivary cortisol measurements are particularly useful to investigate cyclical Cushing's syndrome. At least partial autonomy of cortisol production (either direct from the adrenal cortex or ...

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.

The US FDA has approved a new orphan drug to treat patients with Cushing’s disease who cannot be helped through surgery. Novartis’ Signifor (pasireotide diaspartate) injection has been ...

"Moon face" describes swelling that makes the face puffy and round, like a full moon. It is often caused by long-term use of a steroid medication such as prednisone, but it can also be a symptom of a ...

In what the HSA described in a Nov 27 statement as a “first-of-its-kind large-scale collaboration with online platform ...

Total third-quarter revenue of $54 million was led by triple-digit percentage growth of sales of Recorlev, a cortisol ...

These are option for when two or more potential donors aren't compatible with their friend or family member and donate their ...

Dear D.B.: This is a very touching story, and I hope to help readers understand a few points. Autosomal dominant polycystic ...

Corcept Therapeutics has shared some results from its Phase III GRADIENT trial for relacorilant – its experimental treatment for Cushing’s syndrome caused by adrenal gland pathology. The trial will be ...